Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

US8101754B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Liliane Unger · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Armin Beyerbach · Bad Dürkheim, DE
• Karla Drescher · Ludwigshafen, DE
• Wilfried Braje · Ludwigshafen, DE
• John Darbyshire · Allschwil, CH
• Sean Colm Turner · Ludwigshafen, DE
• Gisela Backfisch · Dossenheim, DE

Key dates

• Filing date: Dec 1, 2005
• Grant date: Jan 24, 2012
• Expiry date: Dec 1, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the formula I:wherein The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.